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Background: To examine duration of daily filgrastim prophylaxis, and risk and consequences of
chemotherapy-induced neutropenic complications (CINC) requiring inpatient care.
Methods: Using a retrospective cohort design and US healthcare claims data (2001–2010), we identified all cancer
patients who initiated ≥1 course of myelosuppressive chemotherapy and received daily filgrastim prophylactically
in ≥1 cycle. Cycles with daily filgrastim prophylaxis were pooled for analyses. CINC was identified based on hospital
admissions with a diagnosis of neutropenia, fever, or infection; consequences were characterized in terms of
hospital mortality, hospital length of stay (LOS), and CINC-related healthcare expenditures.
Results: Risk of CINC requiring inpatient care–adjusted for patient characteristics–was 2.4 (95% CI: 1.6-3.4) and
1.9 (1.3-2.8) times higher with 1–3 (N = 8371) and 4–6 (N = 3691) days of filgrastim prophylaxis, respectively,
versus ≥7 days (N = 2226). Among subjects who developed CINC, consequences with 1–3 and 4–6 (vs. ≥7) days of
filgrastim prophylaxis were: mortality (8.4% [n/N = 10/119] and 4.0% [3/75] vs. 0% [0/34]); LOS (means: 7.4 [N = 243]
and 7.1 [N = 99] vs. 6.5 [N = 40]); and expenditures (means: $18,912 [N = 225] and $14,907 [N = 94] vs. $13,165
[N = 39]).
Conclusions: In this retrospective evaluation, shorter courses of daily filgrastim prophylaxis were found to be
associated with an increased risk of CINC as well as poorer outcomes among those developing this condition.
Because of the limitations inherent in healthcare claims databases specifically and retrospective evaluations
generally, additional research addressing these limitations is needed to confirm the findings of this study.
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Neutropenia is a common side effect of myelosuppres-
sive chemotherapy that both increases the risk of infec-
tion and diminishes patients’ ability to fight infection.
When neutropenic patients become febrile, the high
likelihood of infection and serious consequences thereof
usually results in hospitalization [1,2]. FN, as well as se-
vere or prolonged neutropenia, also can interfere with
the planned delivery of treatment and adversely affect
important patient outcomes [2-11].* Correspondence: dweycker@pai2.com
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reproduction in any medium, provided the orClinical practice guidelines recommend primary
prophylactic use of a colony-stimulating factor (CSF)–
which has been shown to reduce the risk of FN in clinical
trials–when the risk of FN is 20% or higher [2]. While the
American Society of Clinical Oncology (ASCO) initially
recommended that CSF prophylaxis be administered only
when FN risk is 40% or higher, in 2006, ASCO lowered
the threshold to 20% based on data highlighting the im-
portance of FN-related hospitalization as an outcome and
evidence demonstrating the value of CSF prophylaxis in
reducing the risk of FN, the risk of FN-related
hospitalization, and the associated use of IV anti-infective
agents [2,12,13]. The CSF filgrastim, which is widely usedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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daily administration during each cycle until neutrophil re-
covery occurs (in clinical trials, given typically for 10–11
days [and up to 14 days] until absolute neutrophil count
[ANC] ≥10 × 109/L) [14-19].
In clinical practice, patients often receive shorter
courses of daily filgrastim prophylaxis than those adminis-
tered to subjects in the clinical trial setting [14-16,20-24].
While published studies suggest that shorter courses of
daily filgrastim prophylaxis are associated with an in-
creased risk of hospitalization for CINC, these studies fo-
cused on selected tumor types or employed data that now
are over a decade old [23,24]. During the past decade, use
of chemotherapy and supportive care in clinical practice–
as well as recommended use of these agents in authorita-
tive guidelines–has changed considerably [2,25-27], More-
over, only one study has examined whether CSFs may
favorably impact clinical outcomes and economic costs
when CINC develop despite CSF prophylaxis, and it was
published a decade ago and focused on elderly patients
with a single type of cancer (non-Hodgkin’s lymphoma)
[28]. We therefore undertook a new study to evaluate the
relationship between the duration of daily filgrastim
prophylaxis, and the risk and consequences of CINC re-
quiring inpatient care using a large healthcare claims data-
base. While such databases often lack detailed clinical
information (e.g., on absolute neutrophil counts), they
offer access to information on the health profile and
healthcare utilization of tens of millions of covered lives.Methods
Data source
Patient-level information from two large healthcare claims
databases–the Thomson Reuters MarketScan Commercial
Claims and Encounters and Medicare Supplemental and
Coordination of Benefits Database (MarketScan Database,
2001–2010) and the Intercontinental Marketing Services
LifeLink Database (LifeLink Database, 2001–2008)–were
pooled for analyses. Both databases comprise medical (i.e.,
facility and professional service) and outpatient pharmacy
claims from a large number of participating private health
plans, and each contains claims data for 15 million per-
sons annually.
Data available for each facility and professional-service
claim include date and place of service, diagnoses, pro-
cedures performed/services rendered, and quantity of
services (professional-service claims). Data available for
each retail pharmacy claim include the drug dispensed,
dispensing date, quantity dispensed, and number of days
supplied. All claims also include paid (i.e., reimbursed)
amounts. Selected demographic and eligibility informa-
tion is available for persons in both databases. All data
can be arrayed to provide a detailed chronology of allmedical and pharmacy services used by each plan mem-
ber over time.
The study databases were de-identified prior to their
release to study investigators, as set forth in the corre-
sponding Data Use Agreements. The study databases
have been evaluated and certified by independent third
parties to be in compliance with the Health Insurance
Portability and Accountability Act (HIPAA) of 1996 stat-
istical de-identification standards and to satisfy the con-
ditions set forth in Sections 164.514 (a)-(b) 1ii of the
HIPAA Privacy Rule regarding the determination and
documentation of statistically de-identified data. Use of
the study databases for health services research was
determined–via independent third parties–to be fully
compliant with the HIPAA Privacy Rule and federal
guidance on Public Welfare and the Protection of Hu-
man Subjects [29].
Study population
The study population comprised all patients who initi-
ated ≥1 course of myelosuppressive chemotherapy for a
solid tumor or non-Hodgkin’s lymphoma (NHL) and
who received daily filgrastim prophylaxis during ≥1
cycle. All cycles in which patients received daily filgras-
tim prophylaxis–irrespective of duration–were pooled
for analyses.
Cancer chemotherapy patients
All patients, aged ≥18 years, who began ≥1 new course
of myelosuppressive chemotherapy were identified; the
enrollment window was July 1, 2001 through June 30,
2010 for patients in the MarketScan Database and July
1, 2001 through June 30, 2008 for patients in the Life-
Link Database. Receipt of chemotherapy was ascertained
based on the presence of ≥1 paid medical claim for a
chemotherapy drug or administration thereof (identified
using Healthcare Common Procedure Coding System
[HCPCS], International Classification of Disease, Ninth
Revision, Clinical Modification [ICD-9-CM], and Health
Care Financing Administration Uniform Bill-92 [UB-92]
revenue codes).
Patients were considered to have initiated a new
course of chemotherapy if there was a chemotherapy
claim during the study period that was preceded by a
period ≥60 days without any other claims for chemo-
therapy. Only patients who had evidence of a primary
solid tumor or NHL (based on ≥2 medical claims [≥7
days apart] with a qualifying 3-digit ICD-9-CM diagnosis
code during the period beginning 30 days prior to the
index date and ending 30 days thereafter) were selected.
Chemotherapy courses, cycles, and regimens
For each cancer chemotherapy patient, each unique
cycle within each course of chemotherapy was identified.
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defined as beginning with the date of initiation of
chemotherapy and ending with the first service date for
the next administration of chemotherapy administration
(as evidenced by a medical claim with a corresponding
HCPCS, ICD-9-CM, or UB-92 code) occurring at least
12 days-but no more than 59 days-after the date of initi-
ation of chemotherapy. If a second chemotherapy cycle
did not commence prior to day 60, or if there was evi-
dence of receipt of radiation therapy (based on medical
claims with relevant HCPCS, ICD-9-CM, or UB-92
codes) during this period, both the first cycle of chemo-
therapy and the course of chemotherapy were consid-
ered to have been completed 30 days following the
beginning of the cycle or on the day prior to initiation of
radiation therapy, whichever occurred first. The second
and all subsequent cycles of chemotherapy, as well as
subsequent courses of chemotherapy–if any–during the
period of interest, were similarly defined. A maximum of
8 cycles per course were considered. For patients with
multiple courses of chemotherapy, all qualifying courses
were considered.
Chemotherapy regimens were ascertained based on a
review of all HCPCS Level II codes for parenterally ad-
ministered antineoplastic agents on medical claims with
service dates within 6 days of the start of each cycle of
chemotherapy. Regimens were categorized on a cycle-
specific basis according to the number of agents admin-
istered that are considered to be myelotoxic (list available
from authors upon request).
Daily filgrastim prophylaxis
Cancer chemotherapy patients who received daily fil-
grastim prophylaxis during ≥1 cycle of chemotherapy
were selected for inclusion in the study population. Ad-
ministration of daily filgrastim on or before day 5 of a
given cycle was considered to represent prophylaxis
[14,22,23]. Receipt of daily filgrastim was identified
based on medical claims (J1440, J1441) with relevant
codes from the HCPCS system.
Duration of daily filgrastim prophylaxis during the
patient-cycle was characterized based on temporal pat-
terns of administration; end of prophylaxis was defined
as a gap ≥3 days in its use, outpatient administration of
IV antimicrobial therapy (an indicator for possible
CINC), or hospitalization for CINC. Duration of prophy-
laxis was characterized as 1–3, 4–6, or ≥7 days.
Exclusion criteria
Patient-cycles were excluded from the analytic file if the
following occurred: (1) evidence of ≥2 primary cancers
(solid or blood) within (i.e., +/−) 30 days of chemother-
apy initiation; (2) any gaps in health benefits during the
6-month (“pretreatment”) period prior to chemotherapyinitiation; (3) evidence of hematopoietic stem cell or
bone marrow transplantation prior to or during re-
ceipt of chemotherapy; (4) evidence of chemotherapy
based only on medical claims for administration of the
drugs (HCPCS codes identifying the specific chemo-
therapy agents were not available, and thus the regi-
men and level of myelosuppression could not be
determined); (5) pharmacy claims for myelotoxic
chemotherapy (only drug dispense dates are available
on pharmacy claims, and because pharmacy/medical
claims cannot be definitively linked, precise dates of
chemotherapy administration–needed to characterize
the course and cycles–could not be ascertained); (6)
pharmacy claims for daily filgrastim (precise dates of
administration could not be ascertained, for reasons
stated above); (7) evidence of receipt of sargramostim
(J2820) or pegfilgrastim (C9119, S0135, J2505) during
the first 5 days of the cycle (i.e., as prophylaxis).
Neutropenic complications requiring inpatient care
CINC was identified based on inpatient admissions with
a diagnosis (principal or secondary) of neutropenia
(ICD-9-CM 288.0), fever (780.6), or infection (list avail-
able upon request). Admissions were identified on a
cycle-specific basis using acute-care facility inpatient
claims with admission dates anytime between day 6 and
the last day of the chemotherapy cycle. Episodes of
CINC treated exclusively on an outpatient basis were
not considered. Because CINC that occurred on the day
of the last dose of prophylaxis or the following day could
have resulted in an artificial truncation of a planned lon-
ger course of prophylaxis–and thus could exaggerate the
risk of CINC with shorter courses–analyses were con-
ducted alternatively with and without inclusion of these
patient cycles.
Consequences of CINC requiring inpatient care were
characterized in terms of in-hospital mortality, total hos-
pital LOS (during the cycle), and total CINC-related
healthcare expenditures (i.e., from hospital discharge to
end of cycle). Total CINC-related healthcare expendi-
tures included those for the initial hospitalization as well
as care provided post-discharge on an outpatient basis;
outpatient expenditures comprised encounters with a
diagnosis of neutropenia, fever, or infection, as well as
use/prescriptions for CSF agents (i.e., as treatment) and
antimicrobial therapy. Expenditures were estimated
based on total paid amounts on corresponding claims.
Mortality was characterized using data only from the
MarketScan Database as such information was not avail-
able in the LifeLink Database.
Patient characteristics
Patient characteristics included: age; gender; presence of
selected chronic comorbidities (cardiovascular disease,
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ders (anemia, neutropenia, other), infection, hospitalization
(all-cause and CINC-related, respectively), chemother-
apy, and radiation therapy; pre-chemotherapy healthcare
expenditures; type of cancer, presence of metastases; cycle
number and minimum length of prior cycles; chemother-
apy regimen; receipt of antimicrobial prophylaxis in
the cycle of interest; and year of chemotherapy initiation.
Only observed data were utilized in defining patient
characteristics.
Age was assessed as of the first day of the first cycle of
chemotherapy in the course. Chronic comorbidities and
history of blood disorders, infections, hospitalization,
chemotherapy, radiation therapy, presence of metastases,
and healthcare expenditures were assessed from the be-
ginning of the 6-month pretreatment period through the
first day of the corresponding cycle of chemotherapy. Se-
lected variables (i.e., anemia, neutropenia, other blood
disorders, infections) were alternatively evaluated during
the chemotherapy course (up to the beginning of the
cycle of interest). Metastases (bone vs. other site) and
chronic comorbidities were identified on the basis of ≥1
diagnosis codes on inpatient claims, ≥2 diagnosis codes
on outpatient claims (excluding those for laboratory ser-
vices) on different days, ≥1 procedure codes, and ≥1
drug codes, as appropriate. Blood disorders and infec-
tions were identified on the basis of ≥1 diagnosis codes
(on inpatient and/or outpatient claims) and ≥1 drug
codes, as appropriate. Prophylactic use of antimicrobial
agents was ascertained based on a medical claim for ad-
ministration of drug from cycle day 1 to cycle day 5, or
a pharmacy claim for a filled prescription from cycle
day -3 to cycle day 5, with a corresponding drug code.
Statistical analyses
Incidence of CINC was evaluated for each patient-cycle
in which daily filgrastim was administered prophylactic-
ally, and was estimated by same-cycle duration of
prophylaxis in an unadjusted and adjusted context. For
the latter, a generalized estimating equation (GEE) with
a binomial distribution, logistic link function, and ex-
changeable correlation structure was employed. The
GEE method accounts for correlation among repeated
measures for the same subject (in this instance, across
cycles), while controlling for both fixed characteristics
(e.g., gender) and time-dependent covariates (e.g., first
versus subsequent cycles). All observed patient charac-
teristics were entered into, and retained in, the multi-
variate model. Subgroup and sensitivity analyses
focusing on the first cycle only, employing a narrow def-
inition of CINC (which was identified using the diagno-
sis code for neutropenia only but otherwise the same
algorithm for the broad definition as described above),
and focusing on alternative tumor types separately (i.e.,breast cancer, lung cancer, colorectal cancer, and NHL)
also were conducted.
In-hospital mortality, hospital LOS, and CINC-related
healthcare expenditures among patients who developed
CINC were descriptively evaluated by duration of daily
filgrastim prophylaxis. Confidence intervals (95%) for in-
hospital mortality were computed using the Wilson
score interval; confidence intervals for LOS and eco-
nomic costs were computed using nonparametric boot-
strapping (percentile method) from the study population
(1,000 replicates with replacement). Confidence intervals
for in-hospital mortality, hospital LOS, and healthcare
expenditures were estimated assuming independence be-
tween observations. Only observed data were used in de-
fining study variables; patients who developed CINC but
were missing data on study measures–because such data
either were not recorded on claims or were not provided
by some health plans–were excluded from correspond-
ing analyses.
Results
A total of 135,921 adult patients initiated a new course
of chemotherapy for a solid tumor or NHL during the
period of interest and met all other eligibility criteria.
Among these patients, a total of 5,477 received daily fil-
grastim as prophylaxis during ≥1 cycle of chemotherapy
and thus were included in the study population; these
patients contributed a total of 14,288 daily filgrastim
prophylaxis patient-cycles to the analytic file. Filgrastim
was administered for 1–3 days in 58% of cycles (n =
8,371), 4–6 days in 26% of cycles (n = 3,691), and ≥7days
in 16% of cycles (n = 2,226) (Figure 1).
Mean (SD) age of patients was 54 (13) years for 1–3
days of filgrastim prophylaxis, 57 (14) years for 4–6 days
of prophylaxis, and 56 (13) years for ≥7 days of prophy-
laxis (Table 1). Breast cancer was the most common
tumor type (48% for 1–3 days, 50% for 4–6 days, 49%
for ≥7 days), followed by NHL (10%, 13%, and 13%, re-
spectively), and colorectal cancer (16%, 10%, and 13%,
respectively). Metastatic disease was present in 38% of
patients receiving 1–3 days of prophylaxis, 32% receiving
4–6 days, and 35% receiving ≥7 days. Antimicrobial
agents—principally oral (~90%)—were concurrently used
as prophylaxis in 6.7% of patients receiving 1–3 days of
filgrastim prophylaxis, 7.5% receiving 4–6 days, and
7.5% receiving ≥7 days.
Crude risk of CINC during a cycle of chemotherapy
was 2.9% with 1–3 days of filgrastim prophylaxis, 2.7%
with 4–6 days, and 1.8% with ≥7 days. In adjusted ana-
lyses, the odds of CINC were 2.4 (95% CI: 1.6-3.4) and
1.9 (1.3-2.8) times higher with 1–3 and 4–6 days of fil-
grastim prophylaxis, respectively, versus ≥7 days (refer-
ent group) (Figure 2). Among the subgroup of patients
who developed CINC requiring inpatient care (n = 382),
Figure 1 Days of filgrastim prophylaxis.
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of prophylaxis (n = 243), 7.1 (5.7-8.5) days with 4–6 days
of prophylaxis (n = 99), and 6.5 (4.9-8.0) with ≥7 days of
prophylaxis (n = 40) (Table 2). Among the subgroup of
patients who developed CINC and for whom healthcare
expenditures were available (n = 358), mean total CINC-
related healthcare expenditures were $18,912 (14,570-
23,581) with 1–3 days of prophylaxis (n = 225), $14,907
(11,155-19,728) with 4–6 days (n = 94), and $13,165
(9,595-17,144) with ≥7 days (n = 39). Among the sub-
group of patients who developed CINC and for whom
discharge status was available (n = 228), in-hospital mor-
tality was 8.4% (4.6-14.8) with 1–3 days of prophylaxis
(n-119), 4.0% (1.4-11.1) with 4–6 days (n = 75), and 0%
(0–10.2) with ≥7 days (n = 34).
In subgroup analyses focusing on the first cycle only,
crude risks of CINC were 7.0% with 1–3 days of filgras-
tim prophylaxis (n = 1054), 5.0% with 4–6 days (n = 482),
and 5.2% with ≥7 days (n = 363); in adjusted analyses,
odds of CINC were 1.6 (0.9-2.8) and 1.1 (0.6-2.1) times
higher with 1–3 and 4–6 days (versus ≥7 days) of filgras-
tim prophylaxis in cycle 1 (Table 3). In analyses employ-
ing the narrow definition for CINC, crude risks of CINC
were 1.6% with 1–3 days of filgrastim prophylaxis, 1.8%
with 4–6 days, and 1.3% with ≥7 days; in adjusted ana-
lyses, odds of CINC were 1.6 (1.1-2.5) and 1.7 (1.1-2.7)
times higher with 1–3 and 4–6 days of filgrastim
prophylaxis, respectively, versus ≥7 days. In tumor-
specific analyses, adjusted odds of CINC with 1–3 and
4–6 days of filgrastim prophylaxis (vs. ≥7 days) were: 1.8
(1.0-3.0) and 1.9 (1.1-3.4) for breast cancer; 20.2 (1.9-
212.4) and 14.5 (1.3-158.7) for lung cancer; 1.9 (0.2-16.7)
and 2.5 (0.3-23.5) for colorectal cancer; and 2.1 (1.2-3.6)
and 1.8 (1.0-3.2) for NHL. We note that not all observed
differences were statistically significant in unadjusted
subgroup and secondary analyses, presumably due to the
lack of adjustment for systematic differences in patient
characteristics between prophylaxis subgroups.Discussion
In the largest retrospective study of daily filgrastim use
in US clinical practice, we found that the large majority
of patients undergoing cancer chemotherapy who are
administered prophylaxis with daily filgrastim receive
considerably fewer days of administration than subjects
in clinical trials of daily filgrastim prophylaxis. In our
study population, 95% of patients received fewer than 10
days of filgrastim prophylaxis and 58% received only 1–3
days, versus the typical 10–11 days required for neutro-
phil recovery in the pivotal clinical trials [17-19]. This
finding is largely consistent with observations from other
retrospective clinical practice studies [14-16,22,23]. We
also found that patients who receive shorter courses of
daily filgrastim prophylaxis have a substantially higher
risk of CINC requiring hospitalization. Among patients
in our study population who received 1–3 or 4–6 days
of prophylaxis, the adjusted odds of CINC were 2.4 and
1.9 times, respectively, higher than those receiving ≥7
days. In addition, our study results suggest that, among
the subgroup of patients who develop CINC despite
prophylaxis, the consequences of this condition may be
worse among those who receive fewer administrations of
daily filgrastim prophylaxis. This last set of results
should be interpreted with caution, however, as the
number of patients who developed CINC despite
prophylaxis was, in absolute terms, small.
Over the past decade, the frequency of use of alterna-
tive (often, more myelosuppressive) chemotherapy regi-
mens in US clinical practice has changed considerably,
in large part due to better chemotherapy agents, combi-
nations of agents, and dosing schedules [25-27]. Because
these regimens are typically associated with higher levels
of myelosuppression, use of supportive care–including
CSF prophylaxis–also has increased [27]. While pegfil-
grastim—a longer-acting version of filgrastim that re-
quires only a single dose administered subcutaneously
once per chemotherapy cycle—is now (by far) the most
Table 1 Patient, cancer, and treatment characteristics, by duration of filgrastim prophylaxis
Study population, by days of filgrastim prophylaxis
1-3 (n = 8,371) 4-6 (n = 3,691) > = 7 (n = 2,226)
Patient
Age (years), mean (SD) 54.1 (12.5) 57.4 (13.7) 59.2 (12.9)
Men, % 23.5 23.1 21.7
Chronic comorbidities, %
Cardiovascular disease 1.6 2.0 1.9
Diabetes 8.2 10.2 7.3
Liver disease 1.0 0.9 0.5
Renal disease 0.9 1.0 1.4
History of other Conditions/Events Prior to Chemotherapy Course, %
Anemia 15.2 12.3 14.5
Neutropenia 6.1 5.5 5.7
Other blood disorders 2.2 2.0 2.4
Infection 24.6 33.1 35.8
History of hospitalization for any reason, % 50.6 49.3 49.7
History of CINC-related hospitalization, % 6.6 9.1 10.4
History of chemotherapy, % 9.0 6.4 6.9
History of radiation therapy, % 6.5 4.3 4.0
Pre-Chemotherapy Expenditures ($), Mean ± SD 34,736 (43,618) 33,913 (42,458) 34,480 (43,828)
History of conditions/events in prior cycles of same chemotherapy course, %
Anemia 18.5 18.5 19.6
Neutropenia 38.0 45.4 44.9
Other blood disorders 1.5 1.5 2.2
Infection 31.9 34.2 34.3
Cancer
Type, %
Female breast 48.2 49.6 49.6
Non-Hodgkin’s Lymphoma 9.9 12.8 23.3
Trachea, bronchus, lung 7.5 9.5 8.1
Prostate 0.6 0.5 0.1
Colon/Rectum 15.9 9.8 4.6
Other 17.9 17.9 14.2
Presence of metastases, %
Bone 2.5 1.5 1.8
Other Site 35.1 30.3 29.6
Chemotherapy
Cycle number/min. length of prior cycles in same chemotherapy course, %
1 12.6 13.1 16.3
2/12-19 5.9 4.3 4.8
2/20-26 8.3 10.8 12.1
2/27+ 2.1 3.0 2.7
> = 3/12-19 41.5 31.8 21.1
> = 3/20-26 27.8 35.3 40.5
> = 3/27+ 1.7 1.8 2.5
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Table 1 Patient, cancer, and treatment characteristics, by duration of filgrastim prophylaxis (Continued)
Number of Myelosuppressive Drugs, %
1 24.3 20.0 14.5
2 48.0 48.2 51.3
3 20.6 25.4 31.3
> = 4 7.1 6.4 3.0
Receipt of Antimicrobial Prophylaxis, % 6.7 7.5 7.5
Year of Chemotherapy, %
2001-2003 19.2 19.0 26.9
2004-2006 39.2 34.2 34.2
2007-2010 41.7 46.8 38.9
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practice, filgrastim accounts for a small but important
segment of the prophylactic market [14,16]. In the
present study, 60,600 (45%) of the 135,921 adult cancer
chemotherapy study subjects received CSF prophylaxis
in ≥1cycle during their chemotherapy course. Among
the subgroup who received CSF prophylaxis, 91% re-
ceived pegfilgrastim in ≥1 cycle and 9% received filgras-
tim. Notwithstanding these temporal changes in
chemotherapy regimens and supportive care, however,
our findings regarding the frequent use of shorter
courses of filgrastim prophylaxis and the associated
consequences–based on a study population of over
5,000 patients and nearly 15,000 patient-cycles--are
largely consistent with those reported previously. In the
2006 study by Weycker and colleagues–which included
598 breast cancer, lung cancer, and NHL patients, and
employed data from 1998-2002-- for example, mean
duration of prophylaxis ranged from 4.3 to 6.5 days
across tumor types, while in the Morrison study–which
included 1,451 cancer patients and employed data from1.63 2.35 1.64 3.36




















Figure 2 Adjusted odds ratios for chemotherapy-induced neutropeni
prophylaxis*. *Results adjusted for patient, cancer, and chemotherapy cha2001-2003-- mean duration of prophylaxis ranged from
3.7 to 6.0 days across calendar years and cycles of use
[15,23]. In the present study, mean (SD) duration of
prophylaxis on an overall basis was 3.6 (2.9) days. More-
over, in the aforementioned 2011 study by Weycker
et al., odds of CINC were reported to be 1.5 times higher
for patients receiving <7 versus ≥7 days of filgrastim
prophylaxis, while the corresponding odds ratio in this
study was estimated to be 2.2 (95% CI 1.6-3.1) [14]. We
note that odds ratios for CINC reported above were
largely comparable when limiting attention to the most
recent four-year period (2007–2010): 2.5 (1.5-4.3) with
1–3 versus ≥7 days of filgrastim prophylaxis and 2.2
(1.2-3.9) with 4–6 versus ≥7 days of filgrastim prophy-
laxis. Study results also were robust to alternative speci-
fications of the multivariate model and when excluding
observations for which hospitalizations occurred on the
day of the last dose of daily filgrastim prophylaxis or the
following day.
We expected that systematic differences in the preva-
lence of risk factors (e.g., history of neutropenia, higher0.5 1 1.5 2 2.5 3 3.5 4





c complications requiring inpatient care, by duration of filgrastim
racteristics.
Table 2 Unadjusted risk of inpatient mortality, length of stay in hospital, and healthcare expenditures for
chemotherapy- induced neutropenic complications requiring inpatient care, by duration of filgrastim prophylaxis
Days of Filgrastim Prophylaxis
1-3 4-6 > = 7
Mortality, % (95% CI) 8.4 (4.6-14.8) 4.0 (1.4-11.1) 0.0 (0.0-10.2)
(n = 119) (n = 75) (n = 34)
LOS (days), mean (95% CI) 7.4 (6.4-8.3) 7.1 (5.7-8.5) 6.5 (4.9-8.0)
(n = 243) (n = 99) (n = 40)
Expenditures, mean (95% CI)
Inpatient $18,509 (14,195-23,145) $14,527 (10,758-19,243) $12,544 (9,063-16,315)
Outpatient $226 (126–350) $356 (148–630) $581 (145–1,180)
Pharmacy $177 (68–329) $24 (13–39) $41 (10–88)
Total $18,912 (14,570-23,581) $14,907 (11,155-19,728) $13,165 (9,595-17,144)
(n = 225) (n = 94) (n = 39)
*n’s indicate the number of patient-cycles considered in analyses of study measures; among patients who developed CINC (n = 382), those with missing data on
study measures- because such data were not recorded on claims or were not provided by some health plans- were excluded from corresponding analyses.
**Only patients with paid amounts > $0 were considered in these analyses.
Weycker et al. BMC Health Services Research 2014, 14:189 Page 8 of 11
http://www.biomedcentral.com/1472-6963/14/189doses of chemotherapy agents, metastases to bone, poor
performance status) for CINC would occur according to
the duration of prophylaxis (1–3, 4–6, vs. ≥7 days). We
thus used techniques of multivariate regression to adjust
for such risk factors–to the extent possible–in analyzing
the relationship between duration of daily filgrastim
prophylaxis and outcomes of interest. Given the limita-
tions of the claims-based databases we used, however,
we were forced to use proxies for certain established risk
factors. For example, a proxy measure based on pre-
chemotherapy healthcare expenditures was employed for
performance status, which in prior research has been
shown to be correlated with health status in other pa-
tient populations [30]. Moreover, because information
was not available for some clinically important parame-
ters (e.g., ANC), the possibility exists that the study
groups differed in terms of unobserved characteristics
that predispose to CINC.
We believe that our approach to controlling for such
systematic differences was comprehensive given avail-
able data, and that the above-noted biases–if present–
would confer a conservative bias to analyses. For
example, if the risk of FN is higher among patients re-
ceiving higher doses of chemotherapy (which is unob-
servable in the study database), and these patients are
more likely to receive longer durations of prophylaxis,
then the estimated difference in risk between patients
receiving longer versus shorter courses of prophylaxis
will be smaller than the true or actual difference. That
our adjustment procedures were at least to some extent
successful is suggested by the greater odds ratios for
CINC in the adjusted versus unadjusted analyses, but
uncertainty as to the adequacy of adjustment for con-
founding risk factors is one of the major limitations of
our study.In those instances where code-based operational algo-
rithms were used to identify risk factors of interest (e.g.,
using ICD-9-CM code 288.0 for neutropenia, rather than
ANC) errors of omission/commission in medical coding
may have impacted the accuracy of adjustment. We do
not believe, however, that any such differences or limita-
tions were for the most part systematic in nature. How-
ever, patients who have a history of CINC – and thus
may be more likely to receive longer durations of
prophylaxis – may be more likely to have “neutropenia”
designated as a secondary (or even primary) diagnosis
on future encounters, all else equal.
There is no ICD-9-CM diagnosis code for CINC (i.e.,
neutropenia-related fever or infection), and thus codes
for neutropenia, fever, and infection were employed to
identify hospitalizations assumed to be related to neutro-
penic complications. Patients are typically not given
chemotherapy when they are neutropenic or have active
infection. The timing of fever and infection after chemo-
therapy increases the likelihood that such outcomes are
related to receipt of chemotherapy. Codes for neutro-
penia, fever (surrogate for active infection), and infection
thus are all likely to be related to episodes if seen within
a defined exposure period after receiving chemotherapy.
While the sensitivity of this algorithm for identifying
neutropenic complications is undoubtedly higher than
that of an algorithm using only the ICD-9-CM code for
neutropenia, its specificity and positive predictive value
are unknown.
Other miscellaneous limitations deserve a brief men-
tion. CINC requiring outpatient care were not consid-
ered in our analyses due to the small total number of
events (n = 60). Patients with evidence of receipt of daily
filgrastim via outpatient pharmacy (3% of total) were ex-
cluded because we could not ascertain the precise dates
Table 3 Adjusted odds ratios for chemotherapy- induced neutropenic complications requiring inpatient care in
subgroup and secondary analyses
Unadjusted Adjusted*
No. of cycles No. of events % Odds ratio Odds ratio
Narrow definition of CINC
Days of Filgrastim Prophylaxis
1-3 8,371 130 1.6% 1.15 (0.77,1.72) 1.60 (1.05,2.45)
4-6 3,691 67 1.8% 1.35 (0.88,2.09) 1.74 (1.11,2.72)
> = 7 2,226 30 1.3% – –
Broad definition of CINC
First cycle only
Days of Filgrastim Prophylaxis
1-3 1,054 74 7.0% 1.37 (0.81, 2.30) 1.56 (0.89, 2.74)
4-6 482 24 5.0% 0.95 (0.51, 1.76) 1.11 (0.58, 2.12)
> = 7 363 19 5.2% – –
Breast cancer
Days of Filgrastim Prophylaxis
1-3 4,038 94 2.3% 1.44 (0.86, 2.39) 1.75 (1.02, 3.00)
4-6 1,829 49 2.7% 1.66 (0.96, 2.86) 1.92 (1.09, 3.38)
> = 7 1,103 18 1.6% – –
Lung cancer
Days of Filgrastim Prophylaxis
1-3 630 44 7.0% 13.52 (1.85, 98.79) 20.20 (1.92, 212.36)
4-6 349 15 4.3% 8.08 (1.06, 61.70) 14.54 (1.33, 158.65)
> = 7 181 1 0.6% – –
Colorectal cancer
Days of Filgrastim Prophylaxis
1-3 1,327 21 1.6% 1.64 (0.22, 12.32) 1.88 (0.21, 16.67)
4-6 360 9 2.5% 2.62 (0.33, 20.89) 2.54 (0.27, 23.54)
>=7 103 1 1.0% – –
NHL
Days of Filgrastim Prophylaxis
1-3 830 63 7.6% 1.86 (1.13, 3.05) 2.06 (1.19, 3.55)
4-6 474 28 5.9% 1.42 (0.80, 2.52) 1.76 (0.95, 3.23)
> = 7 519 22 4.2% – –
*Results adjusted for patient, cancer, and treatment characteristic listed in Table 2.
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since use of a general price index may yield spurious
findings when applied to specific patients in specific
health plans who consumed specific healthcare services
and since the distribution of study groups by calendar
year was comparable. Hospital discharge disposition was
available only in the MarketScan Database and informa-
tion concerning LOS or paid amounts was missing for
some hospitalizations. Moreover, we note that a dispro-
portionately high percentage of patients receiving 1–3
days of filgrastim prophylaxis (vs. those receiving 4–6 or
≥7 days) who developed CINC requiring inpatient caredid not have information available on discharge dispos-
ition, and thus the inpatient mortality findings must
be viewed with caution. Although patients initiating “de-
layed” use of daily filgrastim (e.g., after day 5 of the
chemotherapy cycle) have been included in other pub-
lished evaluations, they were not considered in our ana-
lyses as such patients may have received daily filgrastim
for the treatment of CINC (e.g., severe neutropenia) as
opposed to prophylaxis against CINC [15,16]. Finally, we
note that it cannot be determined from outpatient phar-
macy claims data whether drugs dispensed were actually
taken, when they were taken, or how much was taken.
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prophylaxis use (principally oral) may be upwardly
biased and differences in actual use across prophylaxis
subgroups may confound the results of analyses. We also
note, however, that the percentage of patients with filled
prescriptions for antimicrobials was relatively low (and
comparable) across filgrastim prophylaxis subgroups.
Conclusion
In conclusion, we found that among patients receiving
myelosuppressive chemotherapy, shorter courses of daily
filgrastim prophylaxis are associated with increased risk
of CINC. We also found that when CINC develops des-
pite daily filgrastim prophylaxis, the outcomes thereof
may be poorer in those receiving shorter courses of
prophylaxis. Additional research is needed to explore
these relationships among individual tumor types and
chemotherapy regimens.
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